Use of serum sodium for liver transplant graft allocation: A decade in the making, now is it ready for primetime?

Liver Transplantation

Volumn 21, Issue 3, 2015, Pages 279-281

  Biggins, Scott W ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEHAVIOR; CLINICAL OBSERVATION; DECISION MAKING; EDITORIAL; GRAFT SURVIVAL; HUMAN; HYPONATREMIA; LABORATORY TEST; LIVER CIRRHOSIS; LIVER GRAFT; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK FACTOR; SODIUM BLOOD LEVEL; UNITED STATES; BLOOD; END STAGE LIVER DISEASE; FEMALE; LIVER TRANSPLANTATION; MALE;

SODIUM;

END STAGE LIVER DISEASE; FEMALE; HUMANS; HYPONATREMIA; LIVER TRANSPLANTATION; MALE; SODIUM;

EID: 84923603586     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24085     Document Type: Editorial

References (23)

1. Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 1956;271:1121-1125.
2. Earley LE, Sanders CA. The effect of changing serum osmolality on the release of antidiuretic hormone in certain patients with decompensated cirrhosis of the liver and low serum osmolality. J Clin Invest 1959;38:545-550.
3. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003;38(suppl 1):S69-S89.
4. Cosby RL, Yee B, Schrier RW. New classification with prognostic value in cirrhotic patients. Miner Electrolyte Metab 1989;15:261-266.
5. Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-236.
6. Porcel A, Díaz F, Rendón P, Macías M, Martín-Herrera L, Girón-González JA. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med 2002;162: 323-328.
7. Shear L, Kleinerman J, Gabuzda GJ. Renal failure in patients with cirrhosis of the liver. I. clinical and pathologic characteristics. Am J Med 1965;39:184-198.
8. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006;130:1652-1660.
9. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005;41:32-39.
10. Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004;40:802-810.
11. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359:1018-1026.
12. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005;11:336-343.
13. Leise MD, Kim WR, Kremers WK, Larson JJ, Benson JT, Therneau TM. A revised Model for End-Stage Liver Disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology 2011; 140:1952-1960.
14. Barber K1, Madden S, Allen J, Collett D, Neuberger J, Gimson A; for United Kingdom Liver Transplant Selection and Allocation Working Party. Elective liver transplant list mortality: development of a United Kingdom end-stage liver disease score. Transplantation 2011;92:469-476.
15. United Network for Organ Sharing. Executive summary of the minutes, OPTN/UNOS board of directors meeting June 23-24, 2014, Richmond, Virginia. http://optn.transplant.hrsa.gov/converge/ContentDocuments/Executive-Summary-06-2014.pdf. Accessed January 15, 2015.
16. Sharma P, Schaubel DE, Goodrich NP, Merion RM. Serum sodium and the survival benefit of liver transplantation. Liver Transpl 2015.
17. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant 2005;5:307-313.
18. Londoño MC, Guevara M, Rimola A, Navasa M, Taurá P, Mas A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006; 130:1135-1143.
19. Brandman D, Biggins SW, Hameed B, Roberts JP, Terrault NA. Pretransplant severe hepatic encephalopathy, peritransplant sodium and post-liver transplantation morbidity and mortality. Liver Int 2012;32:158-164.
20. Leise MD, Yun BC, Larson JJ, Benson JT, Yang JD, Therneau TM, et al. Effect of the pretransplant serum sodium concentration on outcomes following liver transplantation. Liver Transpl 2014;20:687-697.
21. Yun BC, Kim WR, Benson JT, Biggins SW, Therneau TM, Kremers WK, et al. Impact of pretransplant hyponatremia on outcome following liver transplantation. Hepatology 2009;49:1610-1615.
22. United Network for Organ Sharing. Proposal to add serum sodium to the MELD score. http://optn. transplant.hrsa.gov/PublicComment/pubcommentPropSub-317.pdf. Accessed January 15, 2015.
23. Fisher RA, Heuman DM, Harper AM, Behnke MK, Smith AD, Russo MW, et al. Region 11 MELD Na exception prospective study. Ann Hepatol 2012;11:62-67.